GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that it will present novel preclinical data on SNS-723, a first-in-class CAR-T cell therapy and additional Phase 1 data on the long-term effects of SNS-301, a first-in-class cancer immunotherapy, both targeting a novel tumor specific embryonic antigen, human aspartate β-hydroxylase (ASPH), at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia March 29 – April 3, 2019.

Poster Session Details:

Poster Title: CAR-T cell therapies targeting aspartyl β-hydroxylase (ASPH)
Session Date and Time: Monday, April 1: 1:00-5:00pm ET
Session Title: Adoptive Cell Therapy 2
Location: Exhibit Hall B, Poster Section 22, Poster Board 5
Abstract Number: 2306

Poster Title: Long-term immunogenicity results from a first-in-human study evaluating the anti-ASPH cancer vaccine, SNS-301
Session Date and Time: Monday April 1: 8:00am – 12:00pm ET
Session Title: Cancer Vaccines and Intratumoral Immunomodulation
Location: Exhibit Hall B, Poster Section 22, Poster Board 9
Abstract Number: 1454

About SNS-723

SNS-723 is a first-in-class CAR-T cell therapy that is currently in preclinical development targeting human aspartate β-hydroxylase (ASPH), a cell surface enzyme that is normally expressed during fetal development. The recognition domain of the CAR is the scFv portion of a high affinity anti-ASPH mAb. SNS-723 is designed to overcome one of the major hurdles in T-cell therapy, the identification of antigens that permit effective targeting of tumors in the absence of non-tolerable and/or off-target toxicities to essential tissues and organs. Experiments to further characterize ASPH-targeted CAR-T cells are ongoing with the goal of moving these promising therapeutics into clinic.

About SNS-301

SNS-301 is a first-in-class cancer immunotherapy targeting human aspartate β-hydroxylase (ASPH), a cell surface enzyme that is normally expressed during fetal development. Following fetal development, the protein is no longer expressed. Expression of ASPH is uniquely upregulated in more than 20 different cancer types and promotes cancer cell growth, cell motility and invasiveness. ASPH expression levels in various tumors are inversely correlated with tumor resistance and patient survival. Through enhanced antigen presentation and other engineered immunotherapeutic features, SNS-301 is designed to overcome self- tolerance and induce robust and durable ASPH-specific humoral and cellular immune responses. SNS-301 is paired with a companion diagnostic to select antigen-positive patients and is delivered intradermally for ease of administration.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development for solid tumors and hematological cancers. These programs target ASPH, a novel embryonic antigen. Sensei’s precision medicine approach in immuno-oncology includes the use of companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.

 

Contacts

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie@sternir.com